The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Diagnosis of AIDS with one or more opportunistic infections.
Kaposi's sarcoma with prior history of opportunistic infection.
Stable dose of zidovudine (AZT) therapy.
Preserved pulmonary, renal and hepatic function.
Patients with the following conditions or symptoms are excluded:
Presence of active infection.
Active opportunistic infections.
Central nervous system disorders.
History of seizures.
Irreversible airway disease.
Patients with the following are excluded:
Co-existing conditions and symptoms listed in Patient Exclusion Co-existing Conditions.